Sophiris Bio Inc. (SHS.TO) Reports First Quarter Financial Results and Recent Key Operational Highlights
5/1/2013 6:23:49 AM
More...
|
Sophiris Bio Inc. (SHS.TO) Files Registration Statement for Proposed Initial U.S. Public Offering on the NASDAQ
2/19/2013 9:32:15 AM
More...
|
Sophiris Bio Inc. (SHS.TO) Files for a $75 Million IPO
2/19/2013 8:29:10 AM
More...
|
Sophiris Bio Inc. (SHS.TO) Reports Fourth Quarter and Year-End 2012 Financial Results and Key Operational Highlights
2/14/2013 7:22:20 AM
More...
|
Sophiris Bio Inc. (SHS.TO) Reports Third Quarter Financial Results and Recent Key Operational Highlights
11/13/2012 9:25:48 AM
More...
|
Sophiris Bio Inc. (SHS.TO) to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
11/7/2012 2:27:27 PM
More...
|
Sophiris Bio Inc. (SHS.TO) Announces 12 Month Follow-Up Data From Phase 2b TRIUMPH Clinical Trial of PRX302 in Patients With Benign Prostatic Hyperplasia
10/9/2012 10:41:02 AM
More...
|
Sophiris Bio Inc. (SHS.TO) to Present at the 11th Annual Biotechnology Industry Organization (BIO) Investor Forum
10/4/2012 12:28:51 PM
More...
|
Sophiris Bio Inc. (SHS.TO)'s Drug for Benign Prostatic Hyperplasia Was Well Tolerated Using the Preferred Transrectal Route of Administration
8/31/2012 9:32:17 AM
More...
|